James H Donnell, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 525 Couch Ave, Kirkwood, MO 63122 Phone: 314-966-1500 Fax: 314-966-1681 |
Mark A Mason, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 525 Couch Ave, Kirkwood, MO 63122 Phone: 314-966-1500 Fax: 314-966-1681 |
John C Vandover, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 525 Couch Ave, Kirkwood, MO 63122 Phone: 314-966-1500 Fax: 314-966-1681 |
Robert J Paino, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 525 Couch Ave, Kirkwood, MO 63122 Phone: 314-966-1500 Fax: 314-966-1681 |
John C Strupel, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 525 Couch Ave, Kirkwood, MO 63122 Phone: 314-966-1500 Fax: 314-966-1681 |
Gaetano Venezia, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 525 Couch Ave, Kirkwood, MO 63122 Phone: 314-966-1500 Fax: 314-966-1681 |
Jonas V Grybinas, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 525 Couch Ave, Kirkwood, MO 63122 Phone: 314-966-1500 Fax: 314-966-1681 |
News Archive
Rutgers engineers have embedded high performance electrical circuits inside 3D-printed plastics, which could lead to smaller and versatile drones and better-performing small satellites, biomedical implants and smart structures.
Health care providers, insurance companies and drug makers should make information about prices available to the public, according to a new survey of leaders in health care and health policy.
An overwhelming majority-88 percent-of young adults across the political spectrum think it is important for Congress and the President to pass health reform legislation that would assure affordable health insurance for all and improve health care, according to a Commonwealth Fund survey released today.
Zelos Therapeutics, Inc. has initiated patient dosing in a single dose study of three proprietary subcutaneous formulations of ZT-034 (hPTH (1-34), teriparatide). ZT-034 is being developed to compete with Eli Lilly and Company's Forteo (teriparatide [rDNA origin]) in its existing market of approximately $800M in annual sales in 2008 for the treatment of osteoporosis.
› Verified 5 days ago